Aclaris Therapeutics, Inc.

NASDAQ:ACRS

Biotechnology

Healthcare
$3.50 +0.57%

+$0.03 today

Market cap
$555.14M
Beta
0.80
P/E (TTM)
-8.2
EPS (TTM)
-$0.54
52W Low $1.34High $5.15

Volume 2.94M

Average 1.40M

ACRS EBITDA Margin

EBITDA as a percentage of revenue.

Aclaris Therapeutics, Inc.NASDAQ: ACRS

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin widens to -988.1%

EBITDA Margin was -988.1% in Q1 FY2026, up 225.4 pp from a year earlier. On a trailing-twelve-month basis it was -843.9%, down 542.0 pp year over year. Over 3 fiscal years it narrowed by 540.2 pp.

Context

  • EBITDA Margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 7 analysts of -1148.7% for the fiscal year ending Dec 2026, down from -823.8% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-988.1%+532.6 pp QoQ
Last fiscal yearDec 2025
-823.8%-547.5 pp YoY
LTMMar 2026
-843.9%-542.0 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+225.4 pp-776.3 pp-1001.7 pp
1 year-547.5 pp-324.9 pp+222.6 pp
3 years-540.2 pp-422.4 pp+117.8 pp
5 years+708.2 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-823.8%
Year-over-year change
-547.5pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How ACRS compares with its peers on the latest reported figures

  • ACRS's LTM Mar 2026 EBITDA Margin of -843.9% is the 2nd highest of the 5 companies compared; the peer median is -5450.7%.
  • Its year-over-year change of -542.0 pp is the 2nd highest of 4, against a peer median of -3970.2 pp.
  • Over three fiscal years its change of -540.2 pp compares with a peer median of +1052.7 pp.
ACRS Competitors Peer median
EBITDA Margin for ACRS and competitors
Company Period LTM level YoY 3-year change
ANABAnaptysBio, Inc.LTM Mar 202625.2% +93.4 pp+1052.7 pp
ACRSAclaris Therapeutics, Inc.LTM Mar 2026-843.9% -542.0 pp-540.2 pp
ATTOAttovia Therapeutics, Inc.FY2025-4915.2% ——
ALMSAlumis Inc. Common StockLTM Jun 2026-5986.3% -3970.2 pp—
IFRXInflaRx N.V.LTM Mar 2026-144435.8% -111246.8 pp—
TRAXFirst Tracks Biotherapeutics IncFY2025— ——
MLTXMoonLake ImmunotherapeuticsFY2025— ——
ODTXOdyssey Therapeutics, Inc.—— ——
AGMBAgomAb Therapeutics N.V. American Depositary SharesFY2024— ——
IMUXImmunic, Inc.FY2025— ——
ALDXAldeyra Therapeutics, Inc.FY2025— ——
Peer median (excluding ACRS) -5450.7%-3970.2 pp+1052.7 pp

Competitors are the stored peer set for ACRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6.76M29.75M31.25M18.72M7.83M
Cost of Revenue4.71M11.96M18.08M2.79M2.09M
Gross Profit2.05M17.79M13.17M15.93M5.74M
Gross Margin30.3%59.8%42.1%85.1%73.3%
Research & Development43.81M77.81M98.38M33.59M52.65M
Selling, General & Admin23.62M25.13M31.1M22.2M21.97M
Operating Expenses91.77M107.65M110.53M157.86M82.11M
Depreciation & Amortization923K797K863K807K454K
EBITDA(64.46M)(84.36M)(115.45M)(51.72M)(64.47M)
EBITDA Margin-953.4%-283.5%-369.5%-276.3%-823.8%
Operating Income(89.72M)(89.85M)(97.36M)(141.93M)(76.38M)
Operating Margin-1327.1%-302.0%-311.6%-758.2%-975.9%
Interest Income0007.95M7.64M
Interest Expense00000
Other Income / Expenses(1.14M)2.95M8.51M9.87M11.45M
Income Before Tax(90.87M)(86.91M)(88.85M)(132.07M)(64.92M)
Pre-Tax Margin-1344.0%-292.1%-284.3%-705.5%-829.6%
Income Tax Expense00(367K)00
Net Income(90.87M)(86.91M)(88.48M)(132.07M)(64.92M)
Net Margin-1344.0%-292.1%-283.1%-705.5%-829.6%
EPS (Basic)(1.60)(1.33)(1.27)(1.71)(0.53)
EPS (Diluted)(1.60)(1.33)(1.27)(1.71)(0.53)
Weighted Avg Shares56.73M65.21M69.81M77.3M122.66M
Weighted Avg Shares (Diluted)56.73M65.21M69.81M77.3M122.66M

Aclaris Therapeutics, Inc.

NASDAQ:ACRS

Intrinsic Alpha fair value

Locked

Current Price

$3.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.